within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AE03_Ciprofloxacin;

model Ciprofloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 9.61111111111111e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.103,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.081,
    k12 = 1.2555555555555557e-05,
    k21 = 1.2555555555555557e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ciprofloxacin</td></tr><tr><td>ATC code:</td><td>S01AE03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>103</td><td>L</td></tr>
    <tr><td>clearance:</td><td>34.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a variety of bacterial infections, including urinary tract infections, respiratory tract infections, and eye infections. It is approved for both systemic and ophthalmic uses in many countries.</p><h4>Pharmacokinetics</h4><p>Two-compartment model in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Hirt, D, et al., &amp; Benaboud, S (2021). Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. <i>European journal of clinical pharmacology</i> 77(11) 1687–1695. DOI:<a href=\"https://doi.org/10.1007/s00228-021-03174-1\">10.1007/s00228-021-03174-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34160669/\">https://pubmed.ncbi.nlm.nih.gov/34160669</a></p></li><li><p>Abdulla, A, et al., &amp; Koch, BCP (2020). Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. <i>European journal of clinical pharmacology</i> 76(7) 957–967. DOI:<a href=\"https://doi.org/10.1007/s00228-020-02873-5\">10.1007/s00228-020-02873-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32307575/\">https://pubmed.ncbi.nlm.nih.gov/32307575</a></p></li><li><p>van Rhee, KP, et al., &amp; Knibbe, CAJ (2022). Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical pharmacokinetics</i> 61(8) 1167–1175. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01130-5\">10.1007/s40262-022-01130-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35641862/\">https://pubmed.ncbi.nlm.nih.gov/35641862</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AE03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ciprofloxacin;
